Skip to main content

Dermatology

Progression from Psoriasis to Psoriatic Arthritis

Jun 22, 2021

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).



A retrospecitve analysis of non-randomized moderate-

Read Article

Which patients with psoriasis are at risk to develop PsA?

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.



Many patients do have psoriasis before onset of symptoms. This question can either be explored retrospectively using existing data or

Read Article

Psoriatic arthritis mortality & morbidities

Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Promising options to treat mucocutaneous disease in SLE

Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e. acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE), and nonspecific LE

Read Article
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting. https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2021
OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 06, 2021
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 06, 2021
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate ) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more. https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
Which patients with psoriasis are at risk to develop PsA? The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum. https://t.co/5sj5HSnke3 https://t.co/NwoIoDH5rC
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW

Dr. Rachel Tate @uptoTate( View Tweet )

Jun 05, 2021

EULAR 2021 - Day 2 Podcasts

Jun 04, 2021

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:



1. EULAR2021 - Day2a



Read Article

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jun 04, 2021

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article
Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq
Jun 03, 2021

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Paul Studenic @Stiddyo( View Tweet )
Jun 03, 2021

EULAR 2021 – Day 1 Report

Jun 03, 2021

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Eric Dein @ejdein1( View Tweet )

Jun 02, 2021
New download available! Difficult RA Defined https://t.co/6WGMEiwiUk https://t.co/VTCm4cuyRe
Dr. John Cush @RheumNow( View Tweet )
Jun 02, 2021

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

May 27, 2021

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article

RheumNow Podcast – Myth Busters (5.21.2021)

May 21, 2021

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com




  1. Metanalysis (11 RCTs, 19 registries) of Pulm arterial HTN assoc. w/ CTD (w/ 1,267 & 4,008 CTD-PAH pts), showed Investigational Rxs reduced morbidity/mortality by 36%. CTD-PAH survival

Read Article

IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis

May 17, 2021

Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death. 

Read Article
Increased Methotrexate Liver Disease in Psoriasis https://t.co/sEZajDIkSz

Dr. John Cush @RheumNow( View Tweet )

May 16, 2021
×